金复康口服液对原发性支气管鳞状细胞癌疗效及血清MMP-9的影响

Effects of Jinfukang oral liquid on patients with bronchial squamous carcinoma and its influence on serum MMP-9 levels

目的:研究金复康口服液对支气管鳞状细胞癌患者近期疗效、生存质量及血清基质金属蛋白酶-9(MMP-9)水平的影响。方法:支气管鳞状细胞癌患者45例随机分为常规治疗组(A组,n=23)及常规治疗+金复康口服液组(B组,n=22),观察两组近期疗效(有效率)、患者生存质量(QLQ-LC13量表)及血清MMP-9水平。结果:B组治疗后有效率高于A组约33.60%(P<0.05),QLQ-LC13量表评分下降均大于A组(P<0.05),血清MMP-9水平下降显著高于A组[(11.57±3.26)ng/mL vs.(14.32±3.72)ng/mL](P<0.05)。结论:在常规治疗支气管鳞状细胞癌基础上加用金复康口服液能提高疗效,改善患者生存质量,同时可降低血清MMP-9水平。

Objective： To explore effect of Jinfukang oral liquid on patients with bronchial squamous carcinoma（BSC） and on serum level of matrix metallopeptidase-9（MMP-9）.Methods： Forty-five BSC patients were enrolled and randomly assigned to regular group（Group A,n=23） or regular plus Jinfukang oral liquid group（Group B,n=22）.Effective rate（ER）,quality of life（QOL） and serum MMP-9 levels were assessed.Results： Patients in group B had significantly higher ER（33.59%） than patients in group A（P〈0.05）.Similarly,the decrease of QOL scores and serum MMP-9 level [（11.57±3.26） ng/mL vs.（14.32±3.72） ng/mL] in group B were more significant（P〈0.05）.Conclusions：Combining treatment of Jinfukang oral liquid and standard treatment can decrease MMP-9 level,and improve therapeutical effect and life quality.